Alzheimer Disease: What's New, What's True?

Alzheimer's Disease (AD) affects 55 million people globally and is characterized by brain changes such as amyloid beta and tau aggregation, neuroinflammation, and neuronal death. Despite FDA-approved antibody treatments targeting amyloid-beta, no effective treatment exists, particularly for women and ApoE4 carriers. AD is increasingly seen as a multifactorial disease with neuroinflammation and gut microbiome dysbiosis playing significant roles. Recent studies suggest that pro-inflammatory gut bacteria in prodromal AD are linked to reduced cerebral blood flow and cognitive dysfunction, while beneficial bacteria are associated with better brain health. These findings highlight the potential for novel diagnostic and therapeutic approaches targeting the gut microbiome and inflammation in AD.